Ascendis aims to raise $300M; Basilea inks up to $268M deal with BARDA

Plus, news about GSK, Novo Nordisk, Tanai Therapeutics, Nomic Bio, Brenus Pharma, Xspray, Achilles Therapeutics, BioXcel Therapeutics and Nuvalent:

Ascendis’ $300M offering: The Danish company …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Ocugen plans Phase I/II trials for macular disease gene therapies – Pharmaceutical Technology

Ocugen announced that the manufacturing facility for its regenerative cell therapy for cartilage, NeoCart, is expected for completion by the end of 2023. Image Credit:

August 22, 2023

Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting – Biotech Investments

Issuer: Mainz BioMed N.V. / Key word(s): Conference 28.05.2024 / 14:01 CET/CEST The issuer is solely responsible for the content of this announcement. Mainz Biomed

May 29, 2024

Study shows therapeutic potential of HK for treating degenerative rotator cuff injury in humans

The incidence of degenerative rotator cuff injury in the elderly poses a significant economic burden. A novel study by investigators in The American Journal of

June 20, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.